Alpha Score of 63 reflects moderate overall profile with strong momentum, weak value, strong quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Point72 Steve Cohen | 1.47M | $72.33M | NEW |
| Citadel Ken Griffin | 1.42M | $69.60M | NEW |
| Renaissance Technologies Jim Simons (founder) | 1.04M | $50.78M | NEW |
| Marshall Wace | 381K | $18.68M | NEW |
| D.E. Shaw David Shaw | 6K | $271.9K | NEW |
GSK plc Sponsored ADR represents shares in GSK plc, a global healthcare company headquartered in Middlesex, United Kingdom, and founded in 1715. The company focuses on the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through Commercial Operations and Research and Development segments, with Commercial Operations encompassing specialty medicines, vaccines, and general medicines. GSK plc maintains a strong presence in the pharmaceutical industry, particularly in therapeutic areas such as respiratory conditions, antivirals, and vaccines, while expanding in oncology and immunology. The company leverages joint ventures to enhance scale in markets like HIV treatments. As one of the largest firms by total sales in its sector, GSK plc plays a significant role in addressing global health needs through innovative therapies and preventive solutions, serving diverse markets worldwide.
Earnings calendar coming soon. Subscribe to get notified when GSK reports next.
Get earnings alerts →